Toleranzia AB (TOL) - Total Assets
Based on the latest financial reports, Toleranzia AB (TOL) holds total assets worth Skr183.41 Million SEK (≈ $19.74 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Toleranzia AB (TOL) net assets for net asset value and shareholders' equity analysis.
Toleranzia AB - Total Assets Trend (2012–2024)
This chart illustrates how Toleranzia AB's total assets have evolved over time, based on quarterly financial data.
Toleranzia AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Toleranzia AB's total assets of Skr183.41 Million consist of 8.3% current assets and 91.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 7.4% |
| Accounts Receivable | Skr1.66 Million | 0.9% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr170.74 Million | 91.6% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Toleranzia AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Toleranzia AB (TOL) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Toleranzia AB's current assets represent 8.3% of total assets in 2024, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2024, down from 86.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 91.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 91.6% of total assets.
Toleranzia AB Competitors by Total Assets
Key competitors of Toleranzia AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Toleranzia AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.71 | 0.63 | 19.82 |
| Quick Ratio | 0.71 | 0.70 | 19.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-1.30 Million | Skr-1.95 Million | Skr46.02 Million |
Toleranzia AB - Advanced Valuation Insights
This section examines the relationship between Toleranzia AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.74 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 16.2% |
| Total Assets | Skr186.47 Million |
| Market Capitalization | $13.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Toleranzia AB's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Toleranzia AB's assets grew by 16.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Toleranzia AB (2012–2024)
The table below shows the annual total assets of Toleranzia AB from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr186.47 Million ≈ $20.07 Million |
+16.24% |
| 2023-12-31 | Skr160.43 Million ≈ $17.26 Million |
+27.70% |
| 2022-12-31 | Skr125.63 Million ≈ $13.52 Million |
-4.99% |
| 2021-12-31 | Skr132.23 Million ≈ $14.23 Million |
+82.20% |
| 2020-12-31 | Skr72.58 Million ≈ $7.81 Million |
+87.77% |
| 2019-12-31 | Skr38.65 Million ≈ $4.16 Million |
+27.20% |
| 2018-12-31 | Skr30.39 Million ≈ $3.27 Million |
+81.18% |
| 2017-12-31 | Skr16.77 Million ≈ $1.80 Million |
-24.73% |
| 2016-12-31 | Skr22.28 Million ≈ $2.40 Million |
-18.24% |
| 2015-12-31 | Skr27.26 Million ≈ $2.93 Million |
+769.25% |
| 2014-12-31 | Skr3.14 Million ≈ $337.45K |
+73.78% |
| 2013-12-31 | Skr1.80 Million ≈ $194.18K |
-4.94% |
| 2012-12-31 | Skr1.90 Million ≈ $204.28K |
-- |
About Toleranzia AB
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more